NASDAQ · Drug Manufacturers - General

Grifols, S.A. (GRFS) Stock

$7.27 -0.27% NASDAQ: GRFS Healthcare

Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions.

Valuation

MetricValue
Price$7.27
Market Cap$6.15B
P/E Ratio14.60
P/B Ratio1.11
P/S Ratio0.81
EPS (TTM)$0.50
52-Week High$11.14
52-Week Low$6.96
Dividend Yield1.24%

Financials & Margins

MetricValue
ROE7.88%
ROA2.07%
ROCE7.00%
Gross Margin37.68%
Operating Margin16.89%
Net Margin5.58%
Debt/Equity1.77
Current Ratio2.47

Annual Financials (USD)

Metric20212022202320242025
Revenue$4.9B$6.1B$6.6B$7.2B$7.2B
Operating Profit$595.0M$782.0M$782.0M$1.2B$1.2B
Net Profit$189.0M$185.0M$42.0M$157.0M$386.0M
EPS$0.27$0.31$0.09$0.23$0.57
Op Margin12.1%12.9%11.9%16.5%16.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$19.2B$21.2B$21.0B$21.4B$19.8B
Total Liabilities$11.9B$13.3B$13.5B$12.8B$12.1B
Cash$655.0M$549.0M$530.0M$980.0M$825.0M
Borrowings$10.2B$9.8B$11.0B$10.1B$8.7B

Latest News

European Equities Traded in the US as American Depositary Receipts Advance Wednesday MT Newswires · Jul 15, 2026 European Equities Traded in the US as American Depositary Receipts Decline Friday MT Newswires · Jun 26, 2026 Grifols (GRFS) Launches FESILTY in the U.S. for Congenital Fibrinogen Deficiency Treatment Insider Monkey · Jun 19, 2026 Grifols Launches Fesilty Blood Clotting Concentrate in US MT Newswires · Jun 15, 2026 Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S. GlobeNewswire · Jun 15, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$597.0M$-11.0M$219.0M$902.0M$1.0B
Investing Cash Flow$-1.1B$-2.4B$-705.0M$515.0M$-811.0M
Financing Cash Flow$-196.0M$-69.0M$288.0M$-1.2B$-266.0M
Net Cash Flow$2.1B$-2.1B$-20.0M$450.0M$-39.0M
Free Cash Flow$350.0M$-386.0M$-92.0M$531.0M$751.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.12
EV / EBITDA10.49
FCF Yield12.44%
Quick Ratio0.85
Interest Coverage2.04
Return 1Y-20.15%
Return 3Y-23.15%
Return 5Y-47.30%

Ownership

Insiders Held0.00%
Institutions Held58.23%
Institutions Float Held58.23%
Institutional HolderSharesReport Date
Brandes Investment Partners L.P.36,333,7142026-03-31
Capital World Investors22,924,9902026-03-31
Permian Investment Partners, Lp19,354,6792026-03-31
Black Creek Investment Management Inc.8,386,4522026-03-31
Millennium Management Llc5,005,5322026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ATR $136.77 +2.10% 19.32 $8.73B 1.66%
AVTR $13.36 -2.34% -9.79 $9.04B 0.00%
BIO $330.54 +4.47% 10.29 $8.94B 0.00%
CORT $91.12 -4.45% 146.17 $9.78B 0.00%
DVADaVita Inc. $236.58 +0.48% 23.20 $15.18B 0.00%

About Grifols, S.A.

Grifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.

Grifols, S.A. is headquartered in ES.

Grifols, S.A. (GRFS) stock trades at $7.27 with a market capitalization of $6.15B. The stock is valued at a price-to-earnings (P/E) ratio of 14.60, price-to-book of 1.11, price-to-sales of 0.81. Over the past 52 weeks the stock has ranged between $6.96 and $11.14, and currently trades 34.7% below its 52-week high. It pays a dividend yielding 1.24%.

On profitability, Grifols, S.A. generates a return on equity (ROE) of 7.88%, return on capital employed of 7.00%, an operating margin of 16.89%, a net profit margin of 5.58%.

Official website: www.grifols.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides